Global Live Attenuated Influenza Vaccine (LAIV) Supply, Demand and Key Producers, 2023-2029

Page: 111

Published Date: 19 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global Live Attenuated Influenza Vaccine (LAIV) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Live Attenuated Influenza Vaccine (LAIV) production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Live Attenuated Influenza Vaccine (LAIV), and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Live Attenuated Influenza Vaccine (LAIV) that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Live Attenuated Influenza Vaccine (LAIV) total production and demand, 2018-2029, (K Units)
Global Live Attenuated Influenza Vaccine (LAIV) total production value, 2018-2029, (USD Million)
Global Live Attenuated Influenza Vaccine (LAIV) production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Live Attenuated Influenza Vaccine (LAIV) consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Live Attenuated Influenza Vaccine (LAIV) domestic production, consumption, key domestic manufacturers and share
Global Live Attenuated Influenza Vaccine (LAIV) production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Live Attenuated Influenza Vaccine (LAIV) production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Live Attenuated Influenza Vaccine (LAIV) production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Live Attenuated Influenza Vaccine (LAIV) market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Live Attenuated Influenza Vaccine (LAIV) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Live Attenuated Influenza Vaccine (LAIV) Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Live Attenuated Influenza Vaccine (LAIV) Market, Segmentation by Type
    Trivalent Flu Vaccine
    Quadrivalent Flu Vaccine

Global Live Attenuated Influenza Vaccine (LAIV) Market, Segmentation by Application
    Hospital
    Clinic
    Public Health Agency
    Other

Companies Profiled:
    Sanofi Pasteur
    AstraZeneca
    CSL
    Abbott
    GlaxoSmithKline
    Serum Institute
    Fluenz Tetra
    Cytiva
    BioDiem
    FluMist
    GSK
    ChangChun High & New Technology
    BCHT Biotechnology

Key Questions Answered
1. How big is the global Live Attenuated Influenza Vaccine (LAIV) market?
2. What is the demand of the global Live Attenuated Influenza Vaccine (LAIV) market?
3. What is the year over year growth of the global Live Attenuated Influenza Vaccine (LAIV) market?
4. What is the production and production value of the global Live Attenuated Influenza Vaccine (LAIV) market?
5. Who are the key producers in the global Live Attenuated Influenza Vaccine (LAIV) market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Live Attenuated Influenza Vaccine (LAIV) Introduction
    1.2 World Live Attenuated Influenza Vaccine (LAIV) Supply & Forecast
        1.2.1 World Live Attenuated Influenza Vaccine (LAIV) Production Value (2018 & 2022 & 2029)
        1.2.2 World Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029)
        1.2.3 World Live Attenuated Influenza Vaccine (LAIV) Pricing Trends (2018-2029)
    1.3 World Live Attenuated Influenza Vaccine (LAIV) Production by Region (Based on Production Site)
        1.3.1 World Live Attenuated Influenza Vaccine (LAIV) Production Value by Region (2018-2029)
        1.3.2 World Live Attenuated Influenza Vaccine (LAIV) Production by Region (2018-2029)
        1.3.3 World Live Attenuated Influenza Vaccine (LAIV) Average Price by Region (2018-2029)
        1.3.4 North America Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029)
        1.3.5 Europe Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029)
        1.3.6 China Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029)
        1.3.7 Japan Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Live Attenuated Influenza Vaccine (LAIV) Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Live Attenuated Influenza Vaccine (LAIV) Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Live Attenuated Influenza Vaccine (LAIV) Demand (2018-2029)
    2.2 World Live Attenuated Influenza Vaccine (LAIV) Consumption by Region
        2.2.1 World Live Attenuated Influenza Vaccine (LAIV) Consumption by Region (2018-2023)
        2.2.2 World Live Attenuated Influenza Vaccine (LAIV) Consumption Forecast by Region (2024-2029)
    2.3 United States Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029)
    2.4 China Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029)
    2.5 Europe Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029)
    2.6 Japan Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029)
    2.7 South Korea Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029)
    2.8 ASEAN Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029)
    2.9 India Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029)

3 World Live Attenuated Influenza Vaccine (LAIV) Manufacturers Competitive Analysis
    3.1 World Live Attenuated Influenza Vaccine (LAIV) Production Value by Manufacturer (2018-2023)
    3.2 World Live Attenuated Influenza Vaccine (LAIV) Production by Manufacturer (2018-2023)
    3.3 World Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturer (2018-2023)
    3.4 Live Attenuated Influenza Vaccine (LAIV) Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Live Attenuated Influenza Vaccine (LAIV) in 2022
        3.5.3 Global Concentration Ratios (CR8) for Live Attenuated Influenza Vaccine (LAIV) in 2022
    3.6 Live Attenuated Influenza Vaccine (LAIV) Market: Overall Company Footprint Analysis
        3.6.1 Live Attenuated Influenza Vaccine (LAIV) Market: Region Footprint
        3.6.2 Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Type Footprint
        3.6.3 Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Value Comparison
        4.1.1 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Comparison
        4.2.1 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Consumption Comparison
        4.3.1 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Live Attenuated Influenza Vaccine (LAIV) Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production (2018-2023)
    4.5 China Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers and Market Share
        4.5.1 China Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value (2018-2023)
        4.5.3 China Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production (2018-2023)
    4.6 Rest of World Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production (2018-2023)

5 Market Analysis by Type
    5.1 World Live Attenuated Influenza Vaccine (LAIV) Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Trivalent Flu Vaccine
        5.2.2 Quadrivalent Flu Vaccine
    5.3 Market Segment by Type
        5.3.1 World Live Attenuated Influenza Vaccine (LAIV) Production by Type (2018-2029)
        5.3.2 World Live Attenuated Influenza Vaccine (LAIV) Production Value by Type (2018-2029)
        5.3.3 World Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Live Attenuated Influenza Vaccine (LAIV) Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Clinic
        6.2.3 Public Health Agency
        6.2.4 Other
    6.3 Market Segment by Application
        6.3.1 World Live Attenuated Influenza Vaccine (LAIV) Production by Application (2018-2029)
        6.3.2 World Live Attenuated Influenza Vaccine (LAIV) Production Value by Application (2018-2029)
        6.3.3 World Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2018-2029)

7 Company Profiles
    7.1 Sanofi Pasteur
        7.1.1 Sanofi Pasteur Details
        7.1.2 Sanofi Pasteur Major Business
        7.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 Sanofi Pasteur Recent Developments/Updates
        7.1.6 Sanofi Pasteur Competitive Strengths & Weaknesses
    7.2 AstraZeneca
        7.2.1 AstraZeneca Details
        7.2.2 AstraZeneca Major Business
        7.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 AstraZeneca Recent Developments/Updates
        7.2.6 AstraZeneca Competitive Strengths & Weaknesses
    7.3 CSL
        7.3.1 CSL Details
        7.3.2 CSL Major Business
        7.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 CSL Recent Developments/Updates
        7.3.6 CSL Competitive Strengths & Weaknesses
    7.4 Abbott
        7.4.1 Abbott Details
        7.4.2 Abbott Major Business
        7.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 Abbott Recent Developments/Updates
        7.4.6 Abbott Competitive Strengths & Weaknesses
    7.5 GlaxoSmithKline
        7.5.1 GlaxoSmithKline Details
        7.5.2 GlaxoSmithKline Major Business
        7.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 GlaxoSmithKline Recent Developments/Updates
        7.5.6 GlaxoSmithKline Competitive Strengths & Weaknesses
    7.6 Serum Institute
        7.6.1 Serum Institute Details
        7.6.2 Serum Institute Major Business
        7.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Serum Institute Recent Developments/Updates
        7.6.6 Serum Institute Competitive Strengths & Weaknesses
    7.7 Fluenz Tetra
        7.7.1 Fluenz Tetra Details
        7.7.2 Fluenz Tetra Major Business
        7.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.7.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Fluenz Tetra Recent Developments/Updates
        7.7.6 Fluenz Tetra Competitive Strengths & Weaknesses
    7.8 Cytiva
        7.8.1 Cytiva Details
        7.8.2 Cytiva Major Business
        7.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 Cytiva Recent Developments/Updates
        7.8.6 Cytiva Competitive Strengths & Weaknesses
    7.9 BioDiem
        7.9.1 BioDiem Details
        7.9.2 BioDiem Major Business
        7.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 BioDiem Recent Developments/Updates
        7.9.6 BioDiem Competitive Strengths & Weaknesses
    7.10 FluMist
        7.10.1 FluMist Details
        7.10.2 FluMist Major Business
        7.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.10.5 FluMist Recent Developments/Updates
        7.10.6 FluMist Competitive Strengths & Weaknesses
    7.11 GSK
        7.11.1 GSK Details
        7.11.2 GSK Major Business
        7.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.11.5 GSK Recent Developments/Updates
        7.11.6 GSK Competitive Strengths & Weaknesses
    7.12 ChangChun High & New Technology
        7.12.1 ChangChun High & New Technology Details
        7.12.2 ChangChun High & New Technology Major Business
        7.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.12.5 ChangChun High & New Technology Recent Developments/Updates
        7.12.6 ChangChun High & New Technology Competitive Strengths & Weaknesses
    7.13 BCHT Biotechnology
        7.13.1 BCHT Biotechnology Details
        7.13.2 BCHT Biotechnology Major Business
        7.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
        7.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.13.5 BCHT Biotechnology Recent Developments/Updates
        7.13.6 BCHT Biotechnology Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain
    8.2 Live Attenuated Influenza Vaccine (LAIV) Upstream Analysis
        8.2.1 Live Attenuated Influenza Vaccine (LAIV) Core Raw Materials
        8.2.2 Main Manufacturers of Live Attenuated Influenza Vaccine (LAIV) Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Live Attenuated Influenza Vaccine (LAIV) Production Mode
    8.6 Live Attenuated Influenza Vaccine (LAIV) Procurement Model
    8.7 Live Attenuated Influenza Vaccine (LAIV) Industry Sales Model and Sales Channels
        8.7.1 Live Attenuated Influenza Vaccine (LAIV) Sales Model
        8.7.2 Live Attenuated Influenza Vaccine (LAIV) Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share by Region (2018-2023)
    Table 5. World Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share by Region (2024-2029)
    Table 6. World Live Attenuated Influenza Vaccine (LAIV) Production by Region (2018-2023) & (K Units)
    Table 7. World Live Attenuated Influenza Vaccine (LAIV) Production by Region (2024-2029) & (K Units)
    Table 8. World Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2018-2023)
    Table 9. World Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2024-2029)
    Table 10. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Region (2018-2023) & (US$/Unit)
    Table 11. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Region (2024-2029) & (US$/Unit)
    Table 12. Live Attenuated Influenza Vaccine (LAIV) Major Market Trends
    Table 13. World Live Attenuated Influenza Vaccine (LAIV) Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
    Table 14. World Live Attenuated Influenza Vaccine (LAIV) Consumption by Region (2018-2023) & (K Units)
    Table 15. World Live Attenuated Influenza Vaccine (LAIV) Consumption Forecast by Region (2024-2029) & (K Units)
    Table 16. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Live Attenuated Influenza Vaccine (LAIV) Producers in 2022
    Table 18. World Live Attenuated Influenza Vaccine (LAIV) Production by Manufacturer (2018-2023) & (K Units)
    Table 19. Production Market Share of Key Live Attenuated Influenza Vaccine (LAIV) Producers in 2022
    Table 20. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 21. Global Live Attenuated Influenza Vaccine (LAIV) Company Evaluation Quadrant
    Table 22. World Live Attenuated Influenza Vaccine (LAIV) Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Live Attenuated Influenza Vaccine (LAIV) Production Site of Key Manufacturer
    Table 24. Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Type Footprint
    Table 25. Live Attenuated Influenza Vaccine (LAIV) Market: Company Product Application Footprint
    Table 26. Live Attenuated Influenza Vaccine (LAIV) Competitive Factors
    Table 27. Live Attenuated Influenza Vaccine (LAIV) New Entrant and Capacity Expansion Plans
    Table 28. Live Attenuated Influenza Vaccine (LAIV) Mergers & Acquisitions Activity
    Table 29. United States VS China Live Attenuated Influenza Vaccine (LAIV) Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Live Attenuated Influenza Vaccine (LAIV) Production Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 31. United States VS China Live Attenuated Influenza Vaccine (LAIV) Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 32. United States Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production (2018-2023) & (K Units)
    Table 36. United States Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Market Share (2018-2023)
    Table 37. China Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production (2018-2023) & (K Units)
    Table 41. China Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Market Share (2018-2023)
    Table 42. Rest of World Based Live Attenuated Influenza Vaccine (LAIV) Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production (2018-2023) & (K Units)
    Table 46. Rest of World Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Market Share (2018-2023)
    Table 47. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Live Attenuated Influenza Vaccine (LAIV) Production by Type (2018-2023) & (K Units)
    Table 49. World Live Attenuated Influenza Vaccine (LAIV) Production by Type (2024-2029) & (K Units)
    Table 50. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2018-2023) & (US$/Unit)
    Table 53. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2024-2029) & (US$/Unit)
    Table 54. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Live Attenuated Influenza Vaccine (LAIV) Production by Application (2018-2023) & (K Units)
    Table 56. World Live Attenuated Influenza Vaccine (LAIV) Production by Application (2024-2029) & (K Units)
    Table 57. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2018-2023) & (US$/Unit)
    Table 60. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2024-2029) & (US$/Unit)
    Table 61. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
    Table 62. Sanofi Pasteur Major Business
    Table 63. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 64. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. Sanofi Pasteur Recent Developments/Updates
    Table 66. Sanofi Pasteur Competitive Strengths & Weaknesses
    Table 67. AstraZeneca Basic Information, Manufacturing Base and Competitors
    Table 68. AstraZeneca Major Business
    Table 69. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 70. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. AstraZeneca Recent Developments/Updates
    Table 72. AstraZeneca Competitive Strengths & Weaknesses
    Table 73. CSL Basic Information, Manufacturing Base and Competitors
    Table 74. CSL Major Business
    Table 75. CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 76. CSL Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. CSL Recent Developments/Updates
    Table 78. CSL Competitive Strengths & Weaknesses
    Table 79. Abbott Basic Information, Manufacturing Base and Competitors
    Table 80. Abbott Major Business
    Table 81. Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 82. Abbott Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. Abbott Recent Developments/Updates
    Table 84. Abbott Competitive Strengths & Weaknesses
    Table 85. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
    Table 86. GlaxoSmithKline Major Business
    Table 87. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 88. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. GlaxoSmithKline Recent Developments/Updates
    Table 90. GlaxoSmithKline Competitive Strengths & Weaknesses
    Table 91. Serum Institute Basic Information, Manufacturing Base and Competitors
    Table 92. Serum Institute Major Business
    Table 93. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 94. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. Serum Institute Recent Developments/Updates
    Table 96. Serum Institute Competitive Strengths & Weaknesses
    Table 97. Fluenz Tetra Basic Information, Manufacturing Base and Competitors
    Table 98. Fluenz Tetra Major Business
    Table 99. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 100. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Fluenz Tetra Recent Developments/Updates
    Table 102. Fluenz Tetra Competitive Strengths & Weaknesses
    Table 103. Cytiva Basic Information, Manufacturing Base and Competitors
    Table 104. Cytiva Major Business
    Table 105. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 106. Cytiva Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. Cytiva Recent Developments/Updates
    Table 108. Cytiva Competitive Strengths & Weaknesses
    Table 109. BioDiem Basic Information, Manufacturing Base and Competitors
    Table 110. BioDiem Major Business
    Table 111. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 112. BioDiem Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 113. BioDiem Recent Developments/Updates
    Table 114. BioDiem Competitive Strengths & Weaknesses
    Table 115. FluMist Basic Information, Manufacturing Base and Competitors
    Table 116. FluMist Major Business
    Table 117. FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 118. FluMist Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 119. FluMist Recent Developments/Updates
    Table 120. FluMist Competitive Strengths & Weaknesses
    Table 121. GSK Basic Information, Manufacturing Base and Competitors
    Table 122. GSK Major Business
    Table 123. GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 124. GSK Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 125. GSK Recent Developments/Updates
    Table 126. GSK Competitive Strengths & Weaknesses
    Table 127. ChangChun High & New Technology Basic Information, Manufacturing Base and Competitors
    Table 128. ChangChun High & New Technology Major Business
    Table 129. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 130. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 131. ChangChun High & New Technology Recent Developments/Updates
    Table 132. BCHT Biotechnology Basic Information, Manufacturing Base and Competitors
    Table 133. BCHT Biotechnology Major Business
    Table 134. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
    Table 135. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 136. Global Key Players of Live Attenuated Influenza Vaccine (LAIV) Upstream (Raw Materials)
    Table 137. Live Attenuated Influenza Vaccine (LAIV) Typical Customers
    Table 138. Live Attenuated Influenza Vaccine (LAIV) Typical Distributors
List of Figure
    Figure 1. Live Attenuated Influenza Vaccine (LAIV) Picture
    Figure 2. World Live Attenuated Influenza Vaccine (LAIV) Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Live Attenuated Influenza Vaccine (LAIV) Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029) & (K Units)
    Figure 5. World Live Attenuated Influenza Vaccine (LAIV) Average Price (2018-2029) & (US$/Unit)
    Figure 6. World Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share by Region (2018-2029)
    Figure 7. World Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2018-2029)
    Figure 8. North America Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029) & (K Units)
    Figure 9. Europe Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029) & (K Units)
    Figure 10. China Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029) & (K Units)
    Figure 11. Japan Live Attenuated Influenza Vaccine (LAIV) Production (2018-2029) & (K Units)
    Figure 12. Live Attenuated Influenza Vaccine (LAIV) Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 15. World Live Attenuated Influenza Vaccine (LAIV) Consumption Market Share by Region (2018-2029)
    Figure 16. United States Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 17. China Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 18. Europe Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 19. Japan Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 20. South Korea Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 21. ASEAN Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 22. India Live Attenuated Influenza Vaccine (LAIV) Consumption (2018-2029) & (K Units)
    Figure 23. Producer Shipments of Live Attenuated Influenza Vaccine (LAIV) by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Live Attenuated Influenza Vaccine (LAIV) Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Live Attenuated Influenza Vaccine (LAIV) Markets in 2022
    Figure 26. United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Live Attenuated Influenza Vaccine (LAIV) Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Live Attenuated Influenza Vaccine (LAIV) Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Market Share 2022
    Figure 30. China Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Live Attenuated Influenza Vaccine (LAIV) Production Market Share 2022
    Figure 32. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share by Type in 2022
    Figure 34. Trivalent Flu Vaccine
    Figure 35. Quadrivalent Flu Vaccine
    Figure 36. World Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Type (2018-2029)
    Figure 37. World Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share by Type (2018-2029)
    Figure 38. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Type (2018-2029) & (US$/Unit)
    Figure 39. World Live Attenuated Influenza Vaccine (LAIV) Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 40. World Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share by Application in 2022
    Figure 41. Hospital
    Figure 42. Clinic
    Figure 43. Public Health Agency
    Figure 44. Other
    Figure 45. World Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Application (2018-2029)
    Figure 46. World Live Attenuated Influenza Vaccine (LAIV) Production Value Market Share by Application (2018-2029)
    Figure 47. World Live Attenuated Influenza Vaccine (LAIV) Average Price by Application (2018-2029) & (US$/Unit)
    Figure 48. Live Attenuated Influenza Vaccine (LAIV) Industry Chain
    Figure 49. Live Attenuated Influenza Vaccine (LAIV) Procurement Model
    Figure 50. Live Attenuated Influenza Vaccine (LAIV) Sales Model
    Figure 51. Live Attenuated Influenza Vaccine (LAIV) Sales Channels, Direct Sales, and Distribution
    Figure 52. Methodology
    Figure 53. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Live Attenuated Influenza Vaccine (LAIV) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Live Attenuated Influenza Vaccine (LAIV) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 08 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Live Attenuated Influenza Vaccine (LAIV) market size was valued at USD 7964.6 million in 2023 and is forecast to a readjusted size of USD 12000 million by 2030 with a CAGR of 6.0% during review period.

Product Tags

Live Attenuated Influenza Vaccine (LAIV)

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>